Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study [Yahoo! Finance]
Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks [Yahoo! Finance]
Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)